The U.S. Food and Drug Administration (FDA) on Aug. 31 revised the emergency use authorizations for both the Moderna and Pfizer-BioNTech COVID-19 vaccines to allow bivalent formulations of the vaccines for use as a booster dose at least two months after either a primary or booster vaccination.

Also known as “updated boosters,” the bivalent vaccines carry two messenger RNA components of the SARS-CoV-2 virus: one of the original strain of the virus and one that shares more in common with strains derived from the omicron variant.

The Moderna bivalent vaccine has been authorized for those 18 years of age and older while the Pfizer-BioNTech bivalent vaccine is authorized for those ages 12 and up.

For more information, access the FDA website.

Clinical Topics: Congenital Heart Disease and Pediatric Cardiology, COVID-19 Hub, Prevention, CHD and Pediatrics and Arrhythmias

Keywords: RNA, Messenger, Vaccination, Vaccines, Combined, United States Food and Drug Administration, SARS-CoV-2, COVID-19, Child, Adult, Adolescent

< Back to Listings